CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arbutus Biopharma Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arbutus Biopharma Corp
701 Veterans Circle
Phone: (267) 469-0914p:267 469-0914 WARMINSTER, PA  18974  United States Ticker: ABUSABUS
Business Summary
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
6794 Patent owners and lessors

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director LindsayAndroski 47 2/24/2025 2/24/2025
Chief Financial Officer TuanNguyen 3/28/2025 3/28/2025
Chief Compliance Officer, General Counsel, Secretary J. ChristopherNaftzger 57 7/1/2023 7/1/2023
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
OnCore Biopharma, Inc. 3805 Old Easton Road Doylestown PA United States

Business Names
Business Name
ABUS
Arbutus Biopharma US Holdings, Inc.
OnCore Biopharma, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 44 (As of 12/31/2024)
Outstanding Shares: 191,480,188 (As of 3/25/2025)
Shareholders: 102
Stock Exchange: NASD
Federal Tax Id: 980597776
Fax Number: (604) 419-3201


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025